Schedule 13D/A

Filed by: GASTON-DREYFUS REMI
Total Shares: 147,429,909
Subject Company: Bionik Laboratories Corp - View Complete Ownership History Backtest
Filed as of Date: 08/09/2018
Event Date: 07/24/2018
Overall % Ownership: 36.76

Reporting Persons

Name Sole
Voting Power
Shared
Voting Power
Sole
Dispositive Power
Shared
Dispositive Power
Aggregate
Amount Owned
Percent
of class
Remi GastonDreyfus 166,667 147,263,242 166,667 147,263,242 147,429,909 36.76%
RGD Investissements SAS 130,775,000 0 130,775,000 0 130,775,000 32.75%
Lombard International Assurance SA 16,488,242 0 16,488,242 0 16,488,242 4.19%
View Original Filing on Edgar's

Raw Filing Contents

0001144204-18-043326.txt : 20180809
0001144204-18-043326.hdr.sgml : 20180809
20180809163426
ACCESSION NUMBER:		0001144204-18-043326
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20180809
DATE AS OF CHANGE:		20180809
GROUP MEMBERS:		LOMBARD INTERNATIONAL ASSURANCE SA
GROUP MEMBERS:		RGD INVESTISSEMENTS S.A.S.

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bionik Laboratories Corp.
		CENTRAL INDEX KEY:			0001508381
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				271340346
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-87346
		FILM NUMBER:		181005595

	BUSINESS ADDRESS:	
		STREET 1:		483 BAY STREET
		STREET 2:		N105
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5G2C9
		BUSINESS PHONE:		1.416.640.7887

	MAIL ADDRESS:	
		STREET 1:		483 BAY STREET
		STREET 2:		N105
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5G2C9

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Drywave Technologies, Inc.
		DATE OF NAME CHANGE:	20130814

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Strategic Dental Management Corp.
		DATE OF NAME CHANGE:	20101220

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gaston-Dreyfus Remi
		CENTRAL INDEX KEY:			0001716639

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	MAIL ADDRESS:	
		STREET 1:		46 RUE PIERRE CHARRON
		CITY:			PARIS
		STATE:			I0
		ZIP:			75008
SC 13D/A 1 tv500607_sc13da.htm SC 13D/A
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

 

Bionik Laboratories Corp.

 

(Name of Issuer)

 

Common Stock, par value $0.001 per Share

 

(Title of Class of Securities)

 

09074A109

 

(CUSIP Number)

 

Remi Gaston-Dreyfus

46 rue Pierre Charron

F-75008 Paris, France

+33(0)153931212

 

(Name, Address and Telephone Number of Person Authorized to

Receive Notices and Communications)

 

July 24, 2018

 

(Date of Event which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

 

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No.      09074A109

 

 

1.

Names of Reporting Person:

 

Remi Gaston-Dreyfus

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ¨

(b) ¨

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions):

 

AF

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

¨

6.

Citizenship or Place of Organization:

 

France

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

7.

Sole Voting Power:

 

166,667 (see Item 5)

8.

 

Shared Voting Power:

 

147,263,242 (see Item 5)

9.

 

Sole Dispositive Power:

 

166,667 (see Item 5)

10.

 

Shared Dispositive Power:

 

147,263,242 (see Item 5)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person:

 

147,429,909

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

 

¨

13.

Percent of Class Represented by Amount in Row (11):

 

36.76%

14.

Type of Reporting Person (See Instructions):

 

IN

 

 

 

CUSIP No.      09074A109

 

 

1.

Names of Reporting Person:

 

RGD Investissements S.A.S.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ¨

(b) ¨

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions):

 

PF

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

¨

6.

Citizenship or Place of Organization:

 

France

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

7.

Sole Voting Power:

 

130,775,000 (see Item 5)

8.

 

Shared Voting Power:

 

None

9.

 

Sole Dispositive Power:

 

130,775,000 (see Item 5)

10.

 

Shared Dispositive Power:

 

None

11.

Aggregate Amount Beneficially Owned by Each Reporting Person:

 

130,775,000

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

 

¨

13.

Percent of Class Represented by Amount in Row (11):

 

32.75%

14.

Type of Reporting Person (See Instructions):

 

OO

 

 

 

CUSIP No.      09074A109

 

 

1.

Names of Reporting Person:

 

Lombard International Assurance SA

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ¨

(b) x

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions):

 

PF

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

¨

6.

Citizenship or Place of Organization:

 

Luxembourg

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

7.

Sole Voting Power:

 

16,488,242 (see Item 5)

8.

 

Shared Voting Power:

 

None

9.

 

Sole Dispositive Power:

 

16,488,242 (see Item 5)

10.

 

Shared Dispositive Power:

 

None

11.

Aggregate Amount Beneficially Owned by Each Reporting Person:

 

16,488,242

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

 

x

13.

Percent of Class Represented by Amount in Row (11):

 

4.19%

14.

Type of Reporting Person (See Instructions):

 

OO

 

 

 

 

Item 1. Security and Issuer

 

This amended statement on Schedule 13D (this “Statement”) relates to the issued and outstanding shares of common stock, par value $0.001 per share (the “Company Common Stock”), of Bionik Laboratories Corp., a Delaware corporation (the “Company”). The principal executive offices of the Company are located at 483 Bay Street, N105, Toronto, Ontario M5G 2C9.

 

Item 2. Identity and Background

 

This Statement is filed pursuant to Rule 13d-1 under the Securities Exchange Act of 1934, as amended, by Remi Gaston-Dreyfus, a French citizen, RGD Investissements S.A.S. (“RGD”), a company organized under the laws of France, and Lombard International Assurance SA (“Lombard”, and together with Mr. Gaston-Dreyfus and RGD, the “Reporting Persons”), a company organized under the laws of Luxembourg. Mr. Gaston-Dreyfus is a natural person, and is a member of the Board of Directors of the Company, with an address of 46 rue Pierre Charron, F-75008 Paris France. The address of the principal office of RGD is 46 rue Pierre Charron, F-75008 Paris, France. The address if the principal office of Lombard is 4 Rue Lou Hemmer, L-1748, Luxembourg. The principal business of RGD is as a private investment company. The principal business of Lombard is Life Insurance Company (global wealth planning and succession).

 

The Reporting Persons have not, during the past five years, (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors); or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction where as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to federal or state securities laws or finding any violation with respect to such laws.

  

Item 3. Source and Amount of Funds or Other Consideration

 

In June 2018, the Reporting Persons, through RGD, had subscribed for convertible promissory notes (the “Notes”) issued by the Company and pursuant thereto loaned to the Company an aggregate amount of approximately $1,991,673 (the “Loan”). On July 20, 2018, the Notes issued to RGD converted in accordance with its terms (the “Conversion”) into 43,468,547 shares of Company Common Stock.

 

Item 4. Purpose of Transaction

 

The Reporting Persons acquired beneficial ownership of the securities of the Company for investment purposes only and with no view to their resale or other distribution of any kind. The Reporting Persons may make further debt and/or equity investments in the Company pursuant to future private and/or public offerings by the Company.

 

The Conversion described herein was effected in connection with a larger overall transaction of the Company in which the Company converted convertible promissory notes into an aggregate of 102,509,278 shares of Company Common Stock (which includes the shares issued in the Conversion described herein; the “Note Conversion”), which number of Shares was preliminarily determined on July 24, 2018, of which an aggregate of 94,272,393 shares were issued on July 26, 2018, and 8,236,885 shares were issued on August 8, 2018. The Company has not yet definitively determined the final conversion price, and if, upon such definitive determination, the Company is required to issue additional shares of Company Common Stock to the Reporting Person, the Reporting Person will file an amended Schedule 13D. The Note Conversion resulted in an increase in the Company’s issued and outstanding shares of Company Common Stock and exchangeable shares (which vote with the Company Common Stock as a single class and convert into Company Common Stock on a 1-for-1 basis at the option of the holder) to 391,655,118 shares.

 

Except as set forth above, none of the Reporting Persons have any present plans which relate to or would result in:

 

(a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

 

(b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

 

 

 

 

(c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

 

(d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

 

(e) Any material change in the present capitalization or dividend policy of the Issuer;

 

(f) Any other material change in the issuer’s business or corporate structure including but not limited to, if the Issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the Investment Company Act of 1940;

 

(g) Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person;

 

(h) Causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

 

(i) A class of equity securities of the issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

 

(j) Any action similar to any of those enumerated above.

 

Reference is made to Item 3 herein and hereby is incorporated by reference.

 

Item 5. Interest in Securities of the Issuer

 

(a)-(b) As a result of the Note Conversion, as of August 8, 2018, the Company had an aggregate of 391,655,118 shares of Company Common Stock and exchangeable shares outstanding. The percentage of ownership reported in this Item 5 was calculated in accordance with Rule 13d-3(d)(1)(i) promulgated under the Securities Exchange Act of 1934, as amended, except that all outstanding exchangeable shares are deemed converted into Company Common Stock for purposes of computing the percentage of ownership. The aggregate number and percentage of the class of securities of the Company and the voting and dispositive powers of the Reporting Persons is set forth below:

 

  Remi Gaston-Dreyfus RGD Lombard
Amount beneficially owned: 147,429,909 (1) 130,775,000 (4) 16,488,242 (5)
Percent of class: 36.76% 32.75% 4.19%
Sole power to vote or to direct the vote: 166,667 (2) 130,775,000 (4) 16,488,242 (5)
Shared power to vote or direct the vote: 147,263,242 (3) 0 0
Sole power to dispose or to direct the disposition of: 166,667 (2) 130,775,000 (4) 16,488,242 (5)
Shared power to dispose or to direct the disposition of: 147,263,242 (3) 0 0

 

(1)       Includes shares of Company Common Stock, exchangeable shares, and warrants to purchase shares of Company Common Stock beneficially owned by RGD and Lombard. Mr. Gaston-Dreyfus may be deemed to share voting and investment power over the shares beneficially owned by RGD and Lombard. Also includes options to purchase 166,667 shares of Company Common Stock.

 

(2)       Represents options to purchase shares of Company Common Stock. Does not include options to purchase 83,334 shares of Company Common Stock which are not yet vested.

 

(3)       Includes shares of Company Common Stock, exchangeable shares, and warrants to purchase shares of Company Common Stock beneficially owned by RGD and Lombard. Mr. Gaston-Dreyfus may be deemed to share voting and investment power over the shares beneficially owned by RGD and Lombard.

 

(4)       Includes (i) 749,529 exchangeable shares of the Company and (ii) warrants to purchase 7,619,047 shares of the Company’s common stock. Mr. Gaston-Dreyfus may be deemed to share voting and investment power over the shares beneficially owned by RGD.

 

 

 


(5)       Includes (i) 2,621,362 exchangeable shares of the Company and (ii) warrants to purchase 1,600,640 shares of Company Common Stock. Mr. Gaston-Dreyfus may be deemed to share voting and investment power over the shares beneficially owned by Lombard. Does not include any other shares of Company Common Stock or exchangeable shares that may be held by Lombard not on behalf of Mr. Gaston-Dreyfus, beneficial ownership of which are specifically disclaimed by Mr. Gaston-Dreyfus.

 

(c) Except as described herein, the Reporting Persons have not effected any transaction in the Company’s securities in the past 60 days.

 

(d) and (e) Not applicable

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

 

Reference is made to Items 3 and 4 herein and hereby is incorporated by reference.

 

Item 7. Material to be Filed as Exhibits

 

Not Applicable.

 

 

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

Date: August 9, 2018

 

  /s/ Remi Gaston-Dreyfus  
  Remi Gaston-Dreyfus  
       
       
  RGD Investissements S.A.S.  
       
       
  By: /s/ Remi Gaston-Dreyfus  
  Name: Remi Gaston-Dreyfus  
  Title: President  
       
       
  Lombard International Assurance SA  
       
       
  By: *  
  Name:    
  Title:    

 

 

* Signature for Lombard International Assurance SA to be filed by amendment to this Schedule 13D.

 

 

 

WhaleWisdom Logo

Elevate your investments